NasdaqGS:CSII

Stock Analysis Report

Executive Summary

Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States.

Snowflake

Fundamentals

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Cardiovascular Systems's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.6%

CSII

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

37.4%

CSII

9.9%

US Medical Equipment

0.7%

US Market

CSII outperformed the Medical Equipment industry which returned 9.9% over the past year.

CSII outperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

CSIIIndustryMarket
7 Day-0.6%1.1%-0.6%
30 Day4.8%1.3%2.9%
90 Day19.5%3.0%1.3%
1 Year37.4%37.4%10.8%9.9%2.9%0.7%
3 Year119.7%119.7%70.1%64.9%44.6%35.2%
5 Year96.5%96.5%138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Cardiovascular Systems's share price compared to the market and industry in the last 5 years?


Simply Wall St News

1 month ago | Simply Wall St

Here’s why Cardiovascular Systems, Inc.’s (NASDAQ:CSII) Returns On Capital Matters So Much

Valuation

Is Cardiovascular Systems undervalued based on future cash flows and its price relative to the stock market?

11.93x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Cardiovascular Systems's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Cardiovascular Systems's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Cardiovascular Systems is loss making, we can't compare its value to the US Medical Equipment industry average.

Cardiovascular Systems is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Cardiovascular Systems, we can't assess if its growth is good value.


Price Based on Value of Assets

Cardiovascular Systems is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Cardiovascular Systems expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

58.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Cardiovascular Systems's revenue is expected to grow by 12% yearly, however this is not considered high growth (20% yearly).

Cardiovascular Systems's earnings are expected to grow significantly at over 20% yearly.

Cardiovascular Systems's revenue growth is expected to exceed the United States of America market average.

Cardiovascular Systems's earnings growth is expected to exceed the United States of America market average.

Cardiovascular Systems's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Cardiovascular Systems will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Cardiovascular Systems performed over the past 5 years?

49.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Cardiovascular Systems does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Cardiovascular Systems's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Cardiovascular Systems's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Cardiovascular Systems has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Cardiovascular Systems has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Cardiovascular Systems improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Cardiovascular Systems's financial position?


Financial Position Analysis

Cardiovascular Systems is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Cardiovascular Systems's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Cardiovascular Systems has no debt.

Cardiovascular Systems has no debt compared to 5 years ago when it was 1.6%.


Balance Sheet

High level of physical assets or inventory.

Cardiovascular Systems has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Whilst loss making Cardiovascular Systems has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.

Whilst loss making Cardiovascular Systems has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -67.8% per year.


Next Steps

Dividend

What is Cardiovascular Systems's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Cardiovascular Systems's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Cardiovascular Systems's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Cardiovascular Systems has not reported any payouts.

Unable to verify if Cardiovascular Systems's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Cardiovascular Systems has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Cardiovascular Systems's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Cardiovascular Systems's salary, the management and board of directors tenure and is there insider trading?

2.2yrs

Average management tenure


CEO

Scott Ward (59yo)

3.1yrs

Tenure

US$3,448,339

Compensation

Mr. Scott Raymond Ward, MS, B.Sc., has been the Chief Executive Officer and President of Cardiovascular Systems Inc. since August 16, 2016 and served as an Interim Chief Executive Officer and Interim Presi ...


CEO Compensation Analysis

Scott's remuneration is about average for companies of similar size in United States of America.

Scott's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.2yrs

Average Tenure

51yo

Average Age

The tenure for the Cardiovascular Systems management team is about average.


Board Age and Tenure

4.6yrs

Average Tenure

59yo

Average Age

The tenure for the Cardiovascular Systems board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$86,15305 Nov 18
Martha Aronson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares3,000
Max PriceUS$28.72

Ownership Breakdown


Management Team

  • Sandra Sedo (55yo)

    Chief Compliance Officer

    • Tenure: 2.2yrs
  • Scott Ward (59yo)

    Chairman

    • Tenure: 3.1yrs
    • Compensation: US$3.45m
  • Jack Nielsen

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 0yrs
  • Alexander Rosenstein (47yo)

    General Counsel & Corporate Secretary

    • Tenure: 4.5yrs
    • Compensation: US$711.74k
  • David Whitescarver (61yo)

    Vice President of Corporate Development & Intellectual Property

    • Tenure: 2.3yrs
  • Jeffrey Points (42yo)

    Chief Financial Officer

    • Tenure: 1.6yrs
    • Compensation: US$617.27k
  • Rhonda Robb (51yo)

    Chief Operating Officer

    • Tenure: 1.7yrs
    • Compensation: US$2.40m
  • Ryan Egeland (44yo)

    Chief Medical Officer

    • Tenure: 0yrs
  • Stephen Rempe

    Vice President of Human Resources

    • Tenure: 0.3yrs

Board Members

  • Gus Lawlor (63yo)

    Independent Director

    • Tenure: 10.6yrs
    • Compensation: US$200.00k
  • Scott Ward (59yo)

    Chairman

    • Tenure: 3.1yrs
    • Compensation: US$3.45m
  • Billy Cohn (59yo)

    Director

    • Tenure: 4.6yrs
    • Compensation: US$180.00k
  • Ned Brown (56yo)

    Lead Independent Director

    • Tenure: 3.1yrs
    • Compensation: US$230.00k
  • Brent Blackey (60yo)

    Independent Director

    • Tenure: 12.7yrs
    • Compensation: US$190.00k
  • Martha Aronson (52yo)

    Independent Director

    • Tenure: 2.6yrs
    • Compensation: US$190.00k
  • Erik Paulsen

    Director

    • Tenure: 0.2yrs

Company Information

Cardiovascular Systems, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cardiovascular Systems, Inc.
  • Ticker: CSII
  • Exchange: NasdaqGS
  • Founded: 1989
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$1.782b
  • Shares outstanding: 35.27m
  • Website: https://www.csi360.com

Number of Employees


Location

  • Cardiovascular Systems, Inc.
  • 1225 Old Highway 8 Northwest
  • St. Paul
  • Minnesota
  • 55112
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CSIINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2009

Biography

Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers periphera ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 00:06
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.